Boston Scientific Corporation $BSX Position Lowered by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in Boston Scientific Corporation (NYSE:BSX) by 4.2% during the third quarter, according to its most recent filing with the SEC. The fund owned 3,283,898 shares of the medical equipment provider’s stock after selling 143,977 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.23% of Boston Scientific worth $143,342,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Avantax Planning Partners Inc. grew its position in shares of Boston Scientific by 4.0% during the 1st quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider’s stock valued at $329,000 after acquiring an additional 201 shares during the period. WPG Advisers LLC raised its holdings in shares of Boston Scientific by 11.9% in the 1st quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider’s stock worth $120,000 after purchasing an additional 203 shares during the period. Natural Investments LLC raised its holdings in shares of Boston Scientific by 1.3% in the 2nd quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider’s stock worth $685,000 after purchasing an additional 206 shares during the period. 180 Wealth Advisors LLC lifted its stake in Boston Scientific by 3.6% in the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider’s stock valued at $406,000 after purchasing an additional 223 shares during the last quarter. Finally, MGO One Seven LLC lifted its stake in Boston Scientific by 1.9% in the third quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider’s stock valued at $614,000 after purchasing an additional 260 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other news, Director David Habiger bought 2,100 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $41.93 on Monday. The firm has a market cap of $60.77 billion, a P/E ratio of 17.77, a P/E/G ratio of 1.22 and a beta of 0.58. The firm’s fifty day moving average is $44.78 and its 200 day moving average is $56.88. Boston Scientific Corporation has a 52 week low of $39.57 and a 52 week high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the previous year, the firm posted $0.75 earnings per share. The firm’s revenue for the quarter was up 1.4% on a year-over-year basis. Research analysts predict that Boston Scientific Corporation will post 3.17 earnings per share for the current year.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

Wall Street Analyst Weigh In

BSX has been the subject of a number of recent research reports. The Goldman Sachs Group decreased their target price on Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a research report on Tuesday, July 14th. Stifel Nicolaus cut their price target on Boston Scientific from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, October 26th. Canaccord Genuity Group cut their price target on Boston Scientific from $66.00 to $48.00 and set a “buy” rating for the company in a research note on Thursday. Piper Sandler lowered their price objective on Boston Scientific from $65.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 29th. Finally, Argus downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $61.43.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.